Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age60-90
SponsorCovenant Health, US

About this trial

The goal of this clinical trial is to determine if utilizing the Quest AD-Detect blood test, while patient's are hospitalized for a cognitive diagnosis (such as delirium or encephalopathy), will result in an earlier diagnosis of underlying Alzheimer's disease.

* Will this blood test have the ability to distinguish between Alzheimer's disease and other causes of cognitive impairment in the inpatient setting? * Neurology Clinic will complete a 6-month post-hospitalization follow up with patients who have had the Quest AD-Detect Alzheimer's Disease blood test completed while they were inpatient to discuss the risk assessment portfolio

Eligibility criteria

Qualifiers

Ages 60 to 90 years old

No prior diagnosis of dementia

Currently hospitalized with cognitive diagnosis, including but no limited to; delirium, encephalopathy, etc. thought to be secondary to a toxic/metabolic state

Disqualifiers

Age under 60 years

Prior diagnosis of dementing illness or other organic etiology to cognitive impairment

Trial design

Treatments tested in this trial

  • Quest AD-Detect blood test

Treatment groups

30 Participants
are divided into 1 treatment group

Sponsors and collaborators